ProCE Banner Activity

Testing and Targeting BRCA1/2 in HER2- EBC

Slideset

Get up to date on current and emerging perioperative treatment options for patients with HER2- early breast cancer harboring BRCA mutations.

Released: June 02, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC